Send us a text

The ophthalmology world is taking notice as Nova Eye Medical achieves its strongest US sales quarter ever. In this fascinating conversation with Managing Director Tom Sperling, we unpack the remarkable growth trajectory of their minimally invasive glaucoma treatment technology that's winning over doctors and patients alike.

Sperling reveals the powerful simplicity behind their success: "We have a really good product and a driven sales team. The more doctors that try our product, the more take it up." With approximately 1,300 monthly procedures already and an estimated 20,000-30,000 minimally invasive glaucoma procedures occurring monthly in the US market, Nova Eye's runway for growth appears substantial and sustainable.

The financial transformation is equally impressive, with the glaucoma segment nearly achieving break-even in Q3 – posting just a $30,000 EBITDA loss compared to a $1.8 million loss in the first half. This dramatic improvement stems from enhanced manufacturing processes, resolved supply chain issues, and accelerating sales. Perhaps most exciting is the forecast of break-even performance for the glaucoma segment by second half FY25, with group-wide profitability following shortly thereafter.

Beyond the core glaucoma application, Nova Eye has identified a potentially transformative opportunity in ocular drug delivery. Pharmaceutical companies have approached them about leveraging their iTrack technology for targeted medication delivery within the eye – potentially opening an entirely new revenue stream. With minimal exposure to international trade uncertainties and clear catalysts on the horizon, Nova Eye Medical demonstrates why they're positioning themselves at the forefront of ophthalmic innovation. Listen now to understand how this Australian company is revolutionizing glaucoma treatment globally!